Salipro Biotech AB announced that it has entered into a research collaboration and license agreement with Sanofi on the discovery of therapeutic biologics against a challenging drug target. The collaboration brings together Salipro Biotech's unique expertise in developing stable antigens of GPCRs, ion channels and transporters via its proprietary Salipro® platform with Sanofi's discovery programs to identify biologics with the desired therapeutic properties against a selected target.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
90.94 EUR | -0.07% | +1.11% | +1.31% |
07-05 | Sector Update: Health Care Stocks Steady Premarket Friday | MT |
07-05 | Sector Update: Health Care | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.31% | 123B | |
+56.89% | 809B | |
+39.52% | 624B | |
-6.55% | 351B | |
+7.92% | 289B | |
+13.74% | 240B | |
+13.83% | 220B | |
-0.49% | 219B | |
+7.94% | 166B | |
-2.57% | 157B |
- Stock Market
- Equities
- SAN Stock
- News Sanofi
- Salipro Biotech Enters into Collaboration and License Agreement with Sanofi to Advance Discovery Programs